Molecular Partners, a company based in Zurich, has recently announced an extension of its partnership with Orano Med, a French biotech firm.

The purpose of this partnership is to further the development of targeted cancer therapies that utilize the radioisotope lead-212 (212Pb).

The initial agreement, signed in January, focused on the development of Darpin radiotherapies, which are a type of genetically modified antibody proteins.

The new agreement expands the collaboration to include four research programs, with each company retaining marketing rights for two of them.

Human studies for the ML0712 treatment are scheduled to begin next year.

Despite this partnership expansion, Molecular Partners has stated that it will not have an immediate impact on its financial outlook for 2024.

The company maintains its financing forecasts through 2027 and reported cash and cash equivalents of 140 million Swiss francs as of the end of September, a decrease from 159.1 million at the end of June.